Conference Coverage
Conference Coverage
Most Disadvantaged Least Likely to Receive Thrombolysis
This study offers a potential opportunity to investigate how social determinants of health may affect stroke care.
Conference Coverage
Infant Exposure to MS Drugs via Breastfeeding: New Data
“Our data show infants exposed to these medications through breastfeeding experienced no negative effects on health or development within the...
Conference Coverage
Sleep Apnea Is Hard on the Brain
Patients who reported sleep apnea symptoms were about 50% more likely to also report cognitive issues versus their counterparts without such...
Conference Coverage
In Unexpected Finding, Clemastine Fumarate Linked to Worsening Symptoms in MS
Three patients demonstrated increased disability five times faster than their 18-month baseline, which triggered stoppage of the trial.
Conference Coverage
An Easy, Effective Solution to Exercise-Induced Heat Sensitivity in RRMS?
Compared with placebo, body temperature increase from baseline to exercise stoppage was significantly reduced with aspirin and with acetaminophen...
Conference Coverage
Not Even Secondary Endpoints Support BTK Inhibitor in Phase 3 MS Trial
Conference Coverage
Neurologists Read Signs to Diagnose Functional Neurological Disorders
With training and experience, neurologists can learn the characteristics pointing to an accurate diagnosis of functional neurological disorder.
Conference Coverage
Stem Cell Extension Study Reinforces Signal of Benefit for Progressive MS
At interim analysis, a stem cell extension study shows favorable clinical and biomarker effects for progressive MS.
Conference Coverage
Essential Tremor Tied to a Threefold Increased Risk for Dementia
During the follow-up, the cumulative prevalence of dementia was 18.5%, and the average annual conversion rate of MCI to dementia was 12.2% —...
Conference Coverage
The Power of Patient-Reported Outcomes Is Inhibited by Multiple Barriers
Patient-reported outcomes in multiple sclerosis (MS) matter, but remain underused due to multiple barriers.
Conference Coverage
Randomized Trial Confirms Prognostic Value of Neurofilament Light Chains in MS
ASCLEPIOS substudies find high sNfL levels at 3 and 12 months predictive of future CNS activity in patients with MS.